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Abstract The adipose tissue hormone, leptin, and the neuropep-
tide glucagon-like peptide-1 (7-36) amide (GLP-1) both reduce 
food intake and body weight in rodents. Using dual in situ 
hybridization, long isoform leptin receptor (OB-Rb) was 
localized to GLP-1 neurons originating in the nucleus of the 
solitary tract. ICV injection of the specific GLP-1 receptor 
antagonist, exendin(9-39), at the onset of dark phase, did not 
affect feeding in saline pre-treated controls, but blocked the 
reduction in food intake and body weight of leptin pro-treated 
rats. These findings suggest that GLP-1 neurons are a potential 
target for leptin in its control of feeding. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Leptin, secreted by adipose tissue, reduces food intake and 
body weight through interactions with central nervous system 
(CNS) pathways involved in energy balance, particularly in 
the hypothalamus [1-3]. The nature of these interactions has 
yet to be fully determined, but previous work has identified 
neuropeptide Y (NPY) neurons in the arcuate nucleus (ARC) 
as a target [3-6]. However, there is evidence that other CNS 
pathways regulating feeding may mediate the actions of leptin 
[3,7-11]. 
Glucagon-like peptide-1 (7-36) amide (GLP-1) is produced 
by tissue specific posttranslational processing of preprogluca-
gon in the CNS [12]. In the rodent, preproglucagon mRNA 
and GLP-1-like immunoreactivity (GLP-1-IR) are found in 
nucleus of the solitary tract (NTS) neuronal cell bodies in 
the brainstem, with projections to the para ventricular nucleus 
(PVN) [13]. GLP-1-IR and a single specific GLP-1 receptor 
have also been found throughout the CNS, particularly the 
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hypothalamus and other areas involved in the control of feed-
ing [13-16]. In rodents, acute intracerebroventricular (ICV) 
injection of GLP-1 reduces food intake and chronic adminis-
tration reduces body weight [7,14-18]. Importantly, ICV in-
jection of exendin(9-39), a specific GLP-1 receptor antagonist 
[14,19], increases food intake in several animal models [14,20], 
indicating that endogenous GLP-1 is an inhibitor of feeding. 
We have therefore investigated the hypothesis that leptin 
interacts with GLP-1 neurons in the control of food intake. 
Using a probe specific for the long, signalling variant of the 
leptin receptor (OB-Rb) [2], co-localization of OB-Rb and 
preproglucagon mRNA was examined in the rodent brainstem 
by dual in situ hybridization. The effects of CNS GLP-1 re-
ceptor blockade, using ICV exendin(9-39), on the anorectic 
and weight reducing actions of leptin were then investigated. 
2. Materials and methods 
2.1. PCR and probe synthesis 
An 89 bp probe to the GLP-1 coding region of the preproglucagon 
sequence was generated from mouse brainstem cDNA using specific 
polymerase chain reaction (PCR) primers (5'-GACATGCTGAAGG-
GACCTTTAC-3'; +290-+311 and 5'-GGCCTTTCACCAGCCAC-
S'; +378-+362; GenBank Z46845). Reverse transcription using the 
Superscript Preamplification system (Gibco BRL) was performed on 
1 μg of total RNA extracted using the Microfast Track kit (Invitro-
gen). PCR was performed on a Hybaid Touchdown thermal cycler 
using the following conditions: [94°C (4 min), 1 cycle]; [94°C (1 min), 
48°C (1 min), 72°C (1 min), 35 cycles]; [72°C (10 min), 1 cycle]. The 
PCR reaction was as described previously [2]. Agarose gel electro-
phoresis confirmed the presence of a band of the expected size, which 
was purified using Wizard PCR preps (Promega) and cloned directly 
into pGEM-T (Promega). The sequence and orientation of the insert 
was confirmed by automated sequencing. Plasmids were linearized 
with Sac! or Apal for transcription with T7 or SP6 RNA polymerase 
to generate antisense and sense riboprobes. The probe specific to the 
long intracellular domain of the leptin receptor (OB-Rb), a 533 bp 
product, was generated as described previously [2]. 
2.2. In situ hybridization 
Lean 'Aston' mice were drawn from a colony maintained at the 
Rowett Research Institute. Animals were killed by cervical dislocation 
and brains removed rapidly and frozen on dry ice. The study of OB-
Rb and GLP-1 mRNA co-expression in the brainstem of the mouse 
used techniques described in detail elsewhere [5]. 10 μηι coronal hind-
brain sections were simultaneously hybridized with 35S-labelled OB-
Rb (at concentrations of 1.5-2.5 X107 cpm/ml) and digoxigenin-la-
belled GLP-1 riboprobes at 58°C. After hybridization, slides were 
treated as described previously [5]. Dried slides were coated with 3% 
collodion and autoradiographic emulsion (LM-1; Amersham). Brain-
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Fig. 1. In situ hybridization carried out on mouse hindbrain with 35S-labelled leptin receptor (OB-Rb) and digoxigenin-labelled preproglucagon 
riboprobes. Photomicrographs of bright (A,C,D) or dark (B) field images of the NTS, generated following hybridization of adjacent sections 
with either both antisense probes (A,B,C) or both sense probes (D). The bright field image (A) reveals a cluster of NTS neurons that express 
preproglucagon mRNA (colored product). Silver grains (dark spots in bright field, white spots in dark field) representing OB-Rb mRNA ex-
pression are not visible at this magnification. At higher magnification, NTS neurons expressing both mRNA species are indicated by the associ-
ation of silver grains with purple colored cells (B,C). Image B was obtained from the same cluster of NTS neurons shown in A, and shows 
cells that express both mRNA species (large arrows) as well as those that express OB-Rb but not preproglucagon mRNA (small arrows). Color 
formation or clustering of silver grains is not observed with sense probes (D). Magnification: A X135; B,C,D X650. Abbreviations: CC, cen-
tral canal; NTS, nucleus of the solitary tract. 
stem areas were identified by reference to adjacent stained sections 
and to atlases of the mouse and rat brain. 
2.3. Peptides 
Exendin(9-39) was synthesized using a peptide synthesizer and pu-
rified by reversed phase HPLC as previously described [14]. Recombi-
nant mouse leptin was obtained from Novartis (Basel, Switzerland). 
2.4. ICV cannulation and injection 
Male Wistar rats (250-300 g), obtained from the colony kept at the 
Royal Postgraduate Medical School, were housed in individual cages 
under controlled temperature (21-23°C) and a 12 h light:dark cycle 
(lights on at 07.00 h), with free access to food (RM1 diet, SDS UK 
Ltd) and water. Animals were handled daily each morning at 09.00 h 
with measurement of body weight and food intake. Third ventricle 
cannulation and injection were performed as previously described 
[14,21]. Only animals with correct cannula placement, as confirmed 
by a sustained drinking response to ICV angiotensin II administra-
tion, were included. Compounds were dissolved in 0.9% saline and 
each 10 μΐ injection of peptide or saline was given over 1 min. 
2.5. Effects of ICV leptin and exendin(9-39) on food intake and body 
weight 
Four groups of animals were studied (n = 28-32 per group): (1) 
saline+saline, (2) saline+exendin(9-39), (3) leptin+saline and (4) lep-
tin+exendin(9-39). Animals received an ICV injection of leptin (10 
μg) or saline at 09.00 h on day 1. Animals were returned to their 
cages with food ad libitum, and injected ICV, 10 h later, at the onset 
of dark phase with either exendin(9-39) (100 μg) or saline. Food was 
weighed 2 and 4 h into the dark phase and subsequently each morning 
at 09.00 h for 4 days, when body weight was also measured. This dose 
of leptin produces a maximal effect on food intake [11], a finding 
confirmed by us in preliminary experiments. We have previously 
shown this dose of exendin(9-39) to increase feeding in the fed state 
[14]. 
2.6. Statistical analysis 
Data are presented as means ±S.E.M. Differences between groups 
were initially analyzed using repeated measures ANOVA. When a 
significant group X time effect was found, individual time points 
were analyzed between groups by ANOVA with post hoc Tukey's 
test. Significance was taken as P<0 .05 . 
3. Results 
3.1. In situ hybridization 
Preliminary studies where alternate sections were hybridized 
with 35S-labelled riboprobes to preproglucagon or OB-Rb 
m R N A suggested coexpression of these two genes in the rat 
NTS . However, the low levels of leptin receptor gene expres-
sion on emulsion-coated rat medullary sections required ex-
tended exposures (4-6 months) . This resulted in poor resolu-
tion, preventing confident detection of m R N A co-localization. 
Dual in situ hybridization studies thus concentrated on mur-
ine tissue where leptin receptor m R N A was more abundant 
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(unpublished observations). Preproglucagon mRNA, as deter-
mined by formation of colored digoxigenin product (Fig. 1A), 
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Fig. 2. Eflfects of leptin and exendin(9-39) on cumulative dark phase 
food intake on day 1 (A), total daily food intake (B) and daily 
body weight change relative to day 1 (C). Data presented as 
mean ± S.E.M. On day 1, leptin (10 μg) or saline was injected ICV, 
10 h before onset of dark, followed by exendin(9-39) (100 μg) or 
saline ICV, at the onset of dark phase (»= 28-32 per group) [sali-
ne+saline: · ; saline+exendin(9-39): o; leptin+saline: A ; leptin + 
exendin(9-39): Δ ] . *P<0.05, **P<0.01, ***p< 0.005 leptin+saline 
vs. saline+saline; P<0.05, P< 0.005 leptin+saline vs. leptin+exen-
din(9-39); ηΡ<0.01 leptin+exendin(9-39) vs. saline+exendin(9-39). 
was restricted to a relatively small number of neurons in the 
caudal NTS. OB-Rb mRNA was expressed evenly across a 
wider area of the NTS. The majority, if not all, of the NTS 
neurons that expressed preproglucagon mRNA in sufficient 
quantity to generate a visible colored product also expressed 
the OB-Rb gene, as demonstrated by overlying silver grains 
(Fig. 1B,C). However, only 25-50% of neurons that expressed 
the receptor gene in the NTS also stained positive for prepro-
glucagon mRNA. Colored product and silver grain clusters 
were not observed in the NTS following hybridization with 
the respective sense probes (Fig. ID). 
3.2. Effects of ICV leptin and exendin(9-39) on food intake 
and body weight 
Light phase food intake on day 1 was reduced to a similar 
extent in both leptin pre-treated groups before the second 
injection (6.810.5 g saline+saline, 6.910.5 g saline+exen-
din(9-39), 5.6 + 0.6 g leptin+saline, 5.4 + 0.5 g leptin+exen-
din(9-39); P<0 .01 both leptin vs. both saline pre-treated 
groups). On day 1 no significant increase in dark phase 
food intake was seen after ICV exendin(9-39) administration 
in saline pre-treated animals at any time point (Fig. 2A). The 
total dark phase food intake of the leptin+saline group was 
reduced by 39 + 6% on day 1 (P< 0.001 vs. saline+saline) 
(Fig. 2A). This was prevented by ICV exendin(9-39) admin-
istration (leptin+exendin(9-39): P = NS vs. saline+saline or 
saline+exendin(9-39), P< 0.005 vs. leptin+saline) (Fig. 2A). 
The percentage increase in total dark phase food intake after 
ICV exendin(9-39) administration was significantly greater in 
leptin pre-treated (56+10%) than saline pre-treated animals 
(14 + 8%, P<0.0\). The reversal of the anorectic effect of 
leptin by exendin(9-39) was apparent at 4 h (Fig. 2A), and 
continued over the rest of the dark phase. 24 h food intake on 
the second day, however (Fig. 2B), was similarly reduced by 
28 + 4% in the leptin+saline group (P< 0.001 vs. saline+sa-
line) and by 24 + 3% in the leptin+exendin(9-39) group 
(P< 0.001 vs. saline+saline, P<0.0\ vs. saline+exendin(9-
39), P - NS vs. leptin+saline). By day 3 there was no signifi-
cant difference in food intake between groups (Fig. 2B). Sim-
ilarly, there was no significant effect of exendin(9-39) alone on 
body weight (Fig. 2C), but the reduction in body weight seen 
the day after ICV leptin injection (P<0.01 vs. saline+saline) 
was prevented by ICV exendin(9-39) (leptin+exendin(9-39): 
p = NS vs. saline+saline or saline+exendin(9-39), P < 0.05 vs. 
leptin+saline). 
4. Discussion 
The CNS targets for the anorectic and weight reducing 
actions of leptin have yet to be fully identified, although pre-
vious work has suggested an action on hypothalamic NPY 
neurons. Leptin reduces ARC NPY gene expression and hy-
pothalamic NPY release [3,4,6], [125I]leptin uptake is seen in 
the ARC [22] and co-localization of NPY with leptin receptor 
gene expression can be demonstrated in ARC neurons [5]. 
However, leptin is still active in reducing feeding in the 
NPY knockout mouse and loss of NPY only partially reverses 
the effects of leptin deficiency in the ob/ob, NPY knockout 
cross [6,9]. ICV NPY is also less effective at increasing feeding 
in leptin treated rodents [10,11]. This suggests that leptin may 
interact with non-NPY expressing neurons in its control of 
food intake and body weight. Our work has previously dem-
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onstrated that GLP-1 is an endogenous inhibitor of feeding 
[14], and we therefore tested the hypothesis that CNS GLP-1 
neurons may be a target for leptin. 
GLP-1 neuronal cell bodies were identified in the caudal 
NTS, a site of integration of many humoral and visceral in-
puts, as previously described [13]. In this study the demon-
stration by dual in situ hybridization of OB-Rb mRNA ex-
pression in almost all of the preproglucagon-expressing 
neurons in the NTS supports a possible interaction between 
leptin and CNS GLP-1, analogous to our previous findings 
with NPY neurons in the ARC [5]. The interaction may occur 
in the NTS itself, where c-Fos-like immunoreactivity (c-FLI) 
has been demonstrated following peripheral leptin administra-
tion in the rat [8]. Further co-expression studies will be re-
quired to confirm if these correspond to populations of NTS 
neurons expressing the GLP-1 and/or leptin receptor genes. 
Leptin might also act directly on nerve terminals to alter 
GLP-1 release from NTS projections to the PVN or the 
ARC, ventromedial and dorsomedial nuclei, or amygdala 
[13-15]. Both leptin and GLP-1 lead to neuronal activation 
in the PVN and amygdala, areas involved in feeding regula-
tion [7,8,14]. In addition, some neuronal pathways are acti-
vated only by leptin, and others only by GLP-1 [7]. However 
this does not preclude their direct interaction since both pep-
tides have multiple actions in the CNS [18,23,24]. The nature 
of the OB-Rb expressing neurons in the NTS that do not 
express preproglucagon also awaits further investigation. 
The use of a specific GLP-1 antagonist is important if the 
functional effects of leptin on endogenous GLP-1 are to be 
examined. In this study no significant increase in feeding was 
seen in control animals given ICV exendin(9-39) at the onset 
of dark phase. Similar findings have been seen in the fasted 
state and, with a lower dose, over a 90 minute food restricted 
regime [14,18]. In contrast, ICV administration of exendin(9-
39) at the beginning of the light phase after nocturnal feeding 
increases 2 h food intake [14]. The balance between endoge-
nous GLP-1 activity and the onset and duration of action of 
ICV exendin(9-39) may explain these differences. 
In contrast, ICV exendin(9-39) injection following ICV lep-
tin administration produced a marked increase in total dark 
phase food intake, suggesting an increase in endogenous GLP-
1 activity in these animals. The reduction in dark phase food 
intake and weight loss seen on the first day after ICV leptin 
administration was completely reversed by GLP-1 receptor 
blockade, implying a role for CNS GLP-1 in the anorectic 
and weight reducing effects of leptin. The fact that an increase 
in food intake and body weight with exendin(9-39) was only 
seen after leptin pre-treatment makes it unlikely that exen-
din(9-39) had a non-specific effect in its reversal of leptin 
action. On the second day, food intake was reduced to the 
same degree in the leptin+saline and leptin+exendin(9-39) 
animals, suggesting a normal response to the longer-acting 
ICV leptin after the GLP-1 receptor blockade with ICV ex-
endin(9-39) had diminished. 
The prolonged duration of GLP-1 receptor blockade fol-
lowing ICV exendin(9-39) administration implied by this 
study was confirmed in a separate experiment using exoge-
nous GLP-1. Exendin(9-39) (100 μg) injected ICV 5 h before 
ICV GLP-1 (3 μg) administration at the onset of dark phase 
completely prevented the reduction in 2 h food intake seen 
with ICV GLP-1 alone [saline: 6.5 ±0.4 g, GLP-1: 4.8 ±0.5 g 
(P<0.05 vs. saline), exendin(9-39): 6.9 ±0.4 g (P = NS), ex-
endin(9-39)+GLP-l: 6.3 ±0.4 g (P = NS), unpublished obser-
vations]. 
Acute ICV GLP-1 administration reduces and acute ICV 
exendin(9-39) injection augments ICV NPY-induced feeding 
[14,25]. Chronic ICV exendin(9-39) increases NPY-induced 
weight gain [17]. It is therefore possible that the reduction 
in ICV NPY-induced feeding seen after ICV leptin in rodents 
is due to an increase in endogenous GLP-1 release [10,11]. 
Alternatively, leptin may have a direct effect on NPY-sensitive 
neurons or alter release of other neurotransmitters involved in 
feeding, such as corticotrophin releasing hormone (CRH) [3]. 
Although the GLP-1 receptor knockout mouse displays 
normal feeding behavior [16], it is noteworthy that this is 
also the case with the NPY knockout mouse [9]. Only with 
the leptin deficiency of the NPY — /—, obi ob mouse cross does 
an effect on phenotype for the NPY knockout mouse become 
apparent [6]. The effect of leptin in the GLP-1 receptor knock-
out mouse and its cross with the oblob mouse will therefore be 
of interest. However, the numerous other CNS neuropeptides, 
in addition to NPY and GLP-1, through which leptin might 
act to control feeding (such as CRH, oc-melanocyte stimulat-
ing hormone, melanin concentrating hormone and galanin 
circuits) suggests that redundancy and hierarchy are likely. 
In conclusion, we have demonstrated expression of OB-Rb 
mRNA in GLP-1 neurons originating in the NTS. We have 
shown that the GLP-1 receptor antagonist, exendin(9-39), 
given ICV at the onset of the dark phase, increases dark phase 
feeding in leptin but not saline pre-treated animals, and pre-
vents the anorectic and weight reducing effects of ICV leptin 
administration. This adds further support for a potential role 
of CNS GLP-1 in the control of feeding and body weight, and 
suggests that CNS GLP-1 neurons may be a target for the 
adipose hormone leptin. Further studies are needed to exam-
ine the nature of this interaction. 
Acknowledgements: We wish to thank Michele Chiesi and Nigel Lev-
ens (Novartis, Basel, Switzerland) for providing recombinant mouse 
leptin; the UK Medical Research Council (A.P.G., M.M.H., J.K.H., 
K.M., S.R.B.), Scottish Office Agriculture, Environment and Fisheries 
Department (J.G.M., K.M.M., N.H.), Wellcome Trust (C.S.) for fi-
nancial support; and David Morgan, Sang-Jeon Choi, Toshihiko 
Miyoshi, and David Sunter for their contributions to animal work. 
References 
[1] Campfield, L.A., Smith, F.J., Guisez, Y., Devos, R. and Burn, P. 
(1995) Science 269, 546-549. 
[2] Mercer, J.G., Hoggard, N., Williams, L.M., Lawrence, B., Han-
nah, L.T. and Trayhurn, P. (1996) FEBS Lett. 387, 113-116. 
[3] Schwartz, M.W., Seeley, R.J., Campfield, L.A., Burn, P. and 
Baskin, D.G. (1996) J. Clin. Invest. 98, 1101-1106. 
[4] Stephens, T.W., Basinski, M., Bristow, P.K., Bue-Valleskey, 
J.M., Burgett, S.J., Craft, L., Hale, J., Hoffmann, J., Hsiung, 
H.M., Kriauciunas, A., MacKellar, W., Rosteck, P.R., Schoner, 
B., Smith, D., Tinsley, F.C., Zhang, X.Y. and Heiman, M. (1995) 
Nature 377, 530-532. 
[5] Mercer, J.G., Hoggard, N., Williams, L.M., Lawrence, C.B., 
Hannah, L.T., Morgan, P.J. and Trayhurn, P. (1996) J. Neuro-
endocrinol. 8, 733-735. 
[6] Erickson, J.C., Hollopeter, G. and Palmiter, R.D. (1996) Science 
274, 1704-1707. 
[7] van Dijk, G., Thiele, T.E., Donahey, J.C.K., Campfield, L.A., 
Smith, F.J., Burn, P., Bernstein, I.L., Woods, S.C. and Seeley, 
R.J. (1996) Am. J. Physiol. 40, R1096-R1100. 
[8] Elmquist, J.K., Ahima, R.S., Maratosflier, E., Flier, J.S. and 
Safer, C.B. (1997) Endocrinology 138, 839-842. 
138 A.P. Goldstone et al.lFEBS Letters 415 (1997) 134-138 
[9] Erickson, J.C., Clegg, K.E. and Palmiter, R.D. (1996) Nature 
381, 415^118. 
[10] Smith, F.J., Campfield, L.A., Moschera, J.A., Ballon, P.S. and 
Burn, P. (1996) Nature 382, 307. 
[11] Stricker-Krongrad, A., Chiesi, M., Cumin, F., Spanka, C , 
Whitebread, S., Rentsch, J., Lollmann, B., Hofbauer, K.G. and 
Levens, N. (1997) Obesity Res. 4, 37s. 
[12] Kreymann, B., Ghatei, M.A., Burnet, P., Williams, G., Kanse, 
S., Diani, A.R. and Bloom, S.R. (1989) Brain Res. 502, 325-331. 
[13] Larsen, P.J., Tang-Christensen, M., Hoist, J.J. and Orskov, C. 
(1997) Neuroscience 77, 257-270. 
[14] Turton, M.D., O'Shea, D., Gunn, I., Beak, S.A., Edwards, 
C.M.B., Meeran, K., Choi, S.J., Taylor, G.M., Heath, M.M., 
Lambert, P.D., Wilding, J.P.H., Smith, D.M., Ghatei, M.A., 
Herbert, J. and Bloom, S.R. (1996) Nature 379, 69-72. 
[15] Navarro, M., Rodriquez, D.E., Fonseca, F., Alvarez, E., Cho-
wen, J.A., Zueco, J.A., Gomez, R., Eng, J. and Blazquez, E. 
(1996) J. Neurochem. 67, 1982-1991. 
[16] Scrocchi, L.A., Brown, T.J., MaClusky, N., Brubaker, P.L., 
Auerbach, A.B., Joyner, A.L. and Drucker, D J . (1996) Nat. 
Med. 2, 1254-1258. 
[17] Turton, M.D., Edwards, C.M.B., Meeran, K., O'Shea, D., Gunn, 
I., Heath, M.M., Ghatei, M.A. and Bloom, S.R. (1997) Diabetes 
46, (Suppl. 1) 185A. 
[18] Tang-Christensen, M., Larsen, P.J., Goke, R., Finkjensen, A., 
Jessop, D.S., Moller, M. and Sheikh, S.P. (1996) Am. J. Physiol. 
40, R848-R856. 
[19] Goke, R., Fehmann, H.C., Linn, T., Schmidt, H., Krause, M., 
Eng, J. and Goke, B. (1993) J. Biol. Chem. 268, 19650-19655. 
[20] Gunn, I., O'Shea, D., Turton, M.D., Beak, S.A. and Bloom, S.R. 
(1996) Biochem. Soc. Transac. 24, 581-584. 
[21] Rossi, M., Choi, S.J., O'Shea, D., Miyoshi, T., Ghatei, M.A. and 
Bloom, S.R. (1997) Endocrinology 138, 351-355. 
[22] Banks, W.A., Kastin, A.J., Huang, W., Jaspan, J.B. and Maness, 
L.M. (1996) Peptides 17, 305-311. 
[23] O'Shea, D., Gunn, I., Chen, X., Bloom, S. and Herbert, J. (1996) 
NeuroReport 7, 830-832. 
[24] Ahima, R.S., Prabakaran, D., Mantzoros, C , Qu, D., Lowell, B., 
Maratos-Flier, E. and Flier, J.S. (1996) Nature 382, 250-252. 
[25] Meeran, K., O'Shea, D., Turton, M.D., Heath, M.M., Gunn, I., 
Choi, S.J., Edwards, C.M.B., Small, C , Ghatei, M.A. and 
Bloom, S.R. (1996) Diabetes 45, (Suppl. 2) 170A. 
